Malaysia's drug regulator has given conditional approval for Chinese biopharmaceutical company Sinovac Biotech's (Nasdaq:SVA) COVID-19 vaccine to be used in young people aged between 12 and 17, Reuters news agency reported on Friday.
The health ministry stated that the drugs regulator had advised priority for Sinovac's vaccine among teenagers without co-morbidities or allergy problems, or otherwise deemed unsuitable for the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) vaccine.
Reportedly, teenagers younger than 18 in Malaysia started receiving COVID-19 doses last month, after vaccinations of more than 80% of adults were completed.
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children